Abstract
We performed large-scale genome-wide gene-sleep interaction analyses of lipid levels to identify novel genetic variants underpinning the biomolecular pathways of sleep-associated lipid disturbances and to suggest possible druggable targets. We collected data from 55 cohorts with a combined sample size of 732,564 participants (87% European ancestry) with data on lipid traits (high-density lipoprotein [HDL-c] and low-density lipoprotein [LDL-c] cholesterol and triglycerides [TG]). Short (STST) and long (LTST) total sleep time were defined by the extreme 20% of the age- and sex-standardized values within each cohort. Based on cohort-level summary statistics data, we performed meta-analyses for the one-degree of freedom tests of interaction and two-degree of freedom joint tests of the main and interaction effect. In the cross-population meta-analyses, the one-degree of freedom variant-sleep interaction test identified 10 loci (Pint<5.0e-9) not previously observed for lipids. Of interest, the ASPH locus (TG, LTST) is a target for aspartic and succinic acid metabolism previously shown to improve sleep and cardiovascular risk. The two-degree of freedom analyses identified an additional 7 loci that showed evidence for variant-sleep interaction (Pjoint<5.0e-9 in combination with Pint<6.6e-6). Of these, the SLC8A1 locus (TG, STST) has been considered a potential treatment target for reduction of ischemic damage after acute myocardial infarction. Collectively, the 17 (9 with STST; 8 with LTST) loci identified in this large-scale initiative provides evidence into the biomolecular mechanisms underpinning sleep-duration-associated changes in lipid levels. The identified druggable targets may contribute to the development of novel therapies for dyslipidemia in people with sleep disturbances.
Competing Interest Statement
HJG has received travel grants and speakers honoraria from Neuraxpharm, Servier, Indorsia and Janssen Cilag. LMR is a consultant for the TOPMed Administrative Coordinating Center (through Westat). TDS is co-founder and shareholder of ZOE Ltd. All other co-authors declare to have no conflicts of interest.
Funding Statement
This project was largely supported by two grants from the U.S. National Heart, Lung, and Blood Institute (NHLBI), the National Institutes of Health, R01HL118305 and R01HL156991. Furthermore, RN and DvH were supported by a grant from the Dutch Research Council (NWO, Dutch National Research Agenda, Research along routes by consortia, 2021 to 2026, BioClock: the circadian clock in modern society). This research was supported in part by the Intramural Research Program of the National Human Genome Research Institute in the Center for Research on Genomics and Global Health (CRGGH Z01HG200362). HW and PN were supported by R01HL153814 and R21HL165324. CRGGH is also supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the Center for Information Technology, and the Office of the Director at the National Institutes of Health. DAL and QY contributions were supported by the British Heart Foundation (CH/F/20/90003) and UK Medical Research Council (MC_UU_00032/05). TOK was supported by grants from the Novo Nordisk Foundation (NNF18CC0034900, NNF21SA0072102, NNF22OC0074128, NNF23SA0084103). PBM acknowledges support from the National Institute for Health and Care Research (NIHR) Biomedical Research Centre at Barts (NIHR202330). WJG and JM were supported by PO1CA196569. Study-specific funding information is provided in the online supplement.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
When applicable, the analysis protocol was reviewed and approved by institutional review boards. Each contributing study was approved by local medical ethics committees and each participant provided written informed consent, in line with the declaration of Helsinki. More information on the individual cohorts is presented in the Online Supplement.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵# writing group
Added Million Veteran Program in the author banner. Updated their Acknowledgements.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
